Caris Life Sciences, Inc. (CAI)
NASDAQ:CAI
Want to see CAI full AI Analyst Report?
CAI Stock Chart & Stats
$21.15
--
Market closed
$21.15
--
Day’s Range― - ―
52-Week Range$14.19 - $42.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.07M
Market Cap
$4.85B
Enterprise Value$3.91B
Total Cash (Recent Filing)$823.46M
Total Debt (Recent Filing)$173.00K
Price to Earnings (P/E)142.7
Beta1.82
Next Earnings
Aug 18, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding282,680,700
10 Day Avg. Volume2,769,068
30 Day Avg. Volume3,066,304
Financial Highlights & Ratios
PEG Ratio2.83
Price to Book (P/B)78.14
Price to Sales (P/S)55.55
P/FCF Ratio674.37
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue4.30
Enterprise Value/Gross Profit6.26
Enterprise Value/Ebitda37.38
Forecast
1Y Price Target
$27.92Price Target Upside31.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)0.14
Revenue Forecast (FY)$1.00B
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline And Early Detection DataAnalyst highlights encouraging interim results for the multi-cancer early detection program, which could meaningfully expand future revenue if larger studies validate the initial clinical signals.
New Commercial PartnershipsAnalyst points to a partnership to commercialize a blood-based multi-cancer test and a planned self-pay launch as a new commercial channel that could broaden revenue sources beyond core profiling services.
Revenue Guidance And PricingAnalyst notes management set revenue guidance above market expectations and cited constructive pricing on higher-priced tissue testing, which could sustain revenue per test and lift overall top-line growth.
Bears Say
Accounting Adjustments And Reported GrowthAnalyst warns that some revenue growth was boosted by accounting true-ups from prior periods, raising the risk that headline results may overstate underlying operational momentum.
Commercial Execution And Near-term Profitability RiskAnalyst cautions that planned expansion of the sales force will raise operating expenses and could pressure near-term profitability amid competitor volume volatility and weaker pharma research services.
Valuation And Price TargetAnalyst lowered the price target and trimmed the long-term outlook due to sector valuation compression and more conservative growth assumptions, which could constrain upside for the stock.
Caris Life Sciences, Inc. News
CAI FAQ
What was Caris Life Sciences, Inc.’s price range in the past 12 months?
Caris Life Sciences, Inc. lowest stock price was $14.19 and its highest was $42.50 in the past 12 months.
What is Caris Life Sciences, Inc.’s market cap?
Caris Life Sciences, Inc.’s market cap is $4.85B.
When is Caris Life Sciences, Inc.’s upcoming earnings report date?
Caris Life Sciences, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 68 days.
How were Caris Life Sciences, Inc.’s earnings last quarter?
Caris Life Sciences, Inc. released its earnings results on May 07, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.024 by $0.024.
Is Caris Life Sciences, Inc. overvalued?
According to Wall Street analysts Caris Life Sciences, Inc.’s price is currently Undervalued.
Does Caris Life Sciences, Inc. pay dividends?
Caris Life Sciences, Inc. pays a Quarterly dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Caris Life Sciences, Inc. dividends here
What is Caris Life Sciences, Inc.’s EPS estimate?
Caris Life Sciences, Inc.’s EPS estimate is 0.02.
How many shares outstanding does Caris Life Sciences, Inc. have?
Caris Life Sciences, Inc. has 282,680,700 shares outstanding.
What happened to Caris Life Sciences, Inc.’s price movement after its last earnings report?
Caris Life Sciences, Inc. reported an EPS of $0 in its last earnings report, beating expectations of -$0.024. Following the earnings report the stock price went down -18.599%.
Which hedge fund is a major shareholder of Caris Life Sciences, Inc.?
Currently, no hedge funds are holding shares in CAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Caris Life Sciences, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.92 (31.99% Upside)
$27.92 (31.99% Upside)
Blogger Sentiment
Neutral
CAI Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 349.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $501.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
6.47%
Trailing 12-Months
Asset Growth
298.65%
Trailing 12-Months
Company Description
Caris Life Sciences, Inc.
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
CAI Company Deck
CAI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial and financial momentum: substantial revenue and ASP growth, materially improved gross margins, positive adjusted EBITDA and free cash flow, meaningful balance sheet strength, multiple product launches, and encouraging MCED validation data. Headwinds are predominantly timing and phasing related—sales realignment effects on completed cases, short-term Pharma revenue cadence, and elevated near-term investment and CapEx ahead of new product launches. Reimbursement dynamics remain a watch item despite management's confident position. Overall, the positive operational and financial progress and strategic initiatives outweigh the timing and investment-related challenges.View all CAI earnings summariesCAI Stock 12 Month Forecast
Average Price Target
$27.92
▲(31.99% Upside)
Technical Analysis
Bio-Techne
―
Veracyte
―
Adaptive Biotechnologies
―
Maravai Lifesciences Holdings
―
Recursion Pharmaceuticals
―
Ownership Overview
70.53% Insiders
11.85% Mutual Funds
8.42% Other Institutional Investors
5.42% Public Companies and
Individual Investors